Of these genes, MMP1 appeared to be the most promising driver gene showing significant differential expression in the transformation from healthy to IPF and NSCLC, supporting its potential as a novel therapeutic target for IPF, lung cancer, and IPF-progressed lung cancer. Here, MMP1 is linked to lung carcinoma.